



# *Daily Derivatives*

28 October, 2026

DERIVATIVES

28 October 2026

## Key Indices

| Index     | Close    | Changes (%) |
|-----------|----------|-------------|
| NIFTY     | 22749.75 | -0.02       |
| SENSEX    | 73598.67 | -0.01       |
| BANKNIFTY | 53974.90 | -0.72       |
| INDIA VIX | 16.40    | -4.41       |

## Market Outlook

The key benchmark Nifty50 index witnessed volatile intraday swings on the monthly expiry day but remained range-bound and eventually settled the day with a marginal decline. On the technical front, the index faced selling pressure near its 20-DEMA zone around 22,850, while buying interest emerged near the 22,600 support level. On the derivatives front, the initial OI data for the November series indicated continued call writing at the 22,800 and 23,000 strikes, reinforcing the immediate overhead resistance zone. Meanwhile, on the downside, fresh put writing was also witnessed at the 22,600 strike, which highlighted a crucial support level.



## TRADE IDEA OF THE DAY - CDSL CALL SPREAD

**BUY 23 NOV 1220 CALL  
SELL 23 NOV 1300 CALL**

|             |         |
|-------------|---------|
| Entry Range | 24 – 28 |
| Target      | 47      |
| Stop Loss   | 17      |

## Rationale

- From a technical perspective, CDSL witnessed a recovery from its prolonged 200-WEMA zone, indicating sustained buying interest near its crucial long-term support zone. As long as prices remain resilient above this level, it could provide a foundation for a potential bullish reversal towards the immediate resistance zone of 1320-1350.
- The key momentum indicator, 14-Day RSI, hovered above the 40 mark, while the MACD histograms are fading after forming a peak in negative territory, indicating an early sign of a bullish reversal. The robust bullish momentum would be confirmed by a decisive move above the immediate resistance zone.
- On the derivatives front, a long build-up has been witnessed, with rising prices alongside increasing future open interest, which would reinforce the positive outlook. Sustained buying interest could pave the way towards the 1,300-1,320 zone, as long as prices hold above the 1,170 support.




28 October 2026

# Daily Derivatives

## NIFTY

|                  |          |
|------------------|----------|
| LTP (Future)     | 22807.90 |
| OI (In Lots)     | 239956   |
| CHANGE IN OI (%) | 27.37    |
| PRICE CHANGE (%) | -0.36    |


## NIFTY OI




## BANKNIFTY

|                  |          |
|------------------|----------|
| LTP (Future)     | 54470.00 |
| OI (In Lots)     | 76606    |
| CHANGE IN OI (%) | 29.67    |
| PRICE CHANGE (%) | -0.55    |


## BANKNIFTY OI



## FII's Activity Index Futures



## FII's Long Short Ratio



## Long Buildup

| Name       | LTP    | % Change | OI (Lots) | % OI Change |
|------------|--------|----------|-----------|-------------|
| PGEL       | 503    | 5.68     | 13841     | 42.66       |
| INOXWIND   | 59.1   | 0.29     | 17705     | 42.49       |
| CDSL       | 1225   | 1.55     | 22015     | 32.63       |
| NATIONALUM | 311.95 | 0.19     | 19241     | 30.86       |

## Short Buildup

| Name      | LTP    | % Change | OI (Lots) | % OI Change |
|-----------|--------|----------|-----------|-------------|
| PFC       | 315.35 | -1.68    | 70532     | 36.66       |
| AMBUJACEM | 346    | -7.36    | 59825     | 34.82       |
| SBICARD   | 530.5  | -1.64    | 20959     | 34.02       |
| ADANIET   | 2487.3 | -1.40    | 54631     | 32.49       |

## Breakout Stocks (1 Month High)

| Name       | LTP    | % Change | 22 DAY HIGH |
|------------|--------|----------|-------------|
| ATHERENERG | 1675   | 6.01     | 1616.8      |
| BHARTIARTL | 1968.5 | 3.24     | 1929.5      |
| LAURUSLABS | 2129.6 | 3.53     | 2087.7      |
| INDHOTEL   | 809.45 | 2.68     | 794.5       |

## Breakdown Stocks (1 Month Low)

| Name       | LTP    | % Change | 22 DAY LOW |
|------------|--------|----------|------------|
| MAZDOCK    | 1751.2 | -6.81    | 1837.2     |
| ICICIPRULI | 406.9  | -2.3     | 412.7      |
| BDL        | 995.2  | -3.36    | 1002.7     |
| COCHINSHIP | 1115.2 | -1.61    | 1123.3     |

28 October 2026

*Daily*  
**Derivatives**

## NIFTY 50 - STOCKS KEY LEVELS

| SYMBOL     | R1*   | R2*   | LTP*   | S1*   | S2*  |
|------------|-------|-------|--------|-------|------|
| ADANIENT   | 2530  | 2571  | 2490   | 2440  | 2390 |
| ADANIPTS   | 1765  | 1776  | 1754.5 | 1743  | 1731 |
| APOLLOHOSP | 7907  | 8023  | 7791.5 | 7734  | 7676 |
| ASIANPAINT | 2310  | 2343  | 2277   | 2256  | 2236 |
| AXISBANK   | 1221  | 1237  | 1205.7 | 1198  | 1190 |
| BAJAJ-AUTO | 10495 | 10600 | 10390  | 10180 | 9970 |
| BAJAJFINSV | 1688  | 1699  | 1677   | 1659  | 1641 |
| BAJFINANCE | 922   | 931   | 912    | 905   | 898  |
| BEL        | 373   | 378   | 367.95 | 364   | 360  |
| BHARTIARTL | 2002  | 2024  | 1978.8 | 1933  | 1888 |
| BSE        | 3480  | 3520  | 3441.1 | 3388  | 3336 |
| CIPLA      | 1375  | 1401  | 1350   | 1322  | 1294 |
| COALINDIA  | 403   | 407   | 398    | 396   | 394  |
| DRREDDY    | 1323  | 1335  | 1310   | 1298  | 1287 |
| EICHERMOT  | 7201  | 7237  | 7165   | 7098  | 7032 |
| ETERNAL    | 334   | 337   | 331    | 326   | 321  |
| GRASIM     | 2934  | 2968  | 2900.8 | 2874  | 2847 |
| HCLTECH    | 1430  | 1439  | 1420   | 1401  | 1381 |
| HDFCBANK   | 687   | 695   | 680.2  | 676   | 671  |
| HDFCLIFE   | 520   | 525   | 513.6  | 510   | 506  |
| HINDALCO   | 897   | 902   | 891.2  | 883   | 875  |
| HINDUNILVR | 1838  | 1858  | 1818   | 1778  | 1738 |
| ICICIBANK  | 1399  | 1412  | 1386.9 | 1376  | 1365 |
| INDIGO     | 4649  | 4702  | 4596.5 | 4567  | 4537 |
| INFY       | 1176  | 1189  | 1163   | 1140  | 1116 |

\*R1 - Resistance 1 | \*R2 - Resistance 2 | \*LTP – Last Traded Price | \*S1 - Support 1 | \*S2 - Support 2

28 October 2026

*Daily*  
**Derivatives**

## NIFTY 50 - STOCKS KEY LEVELS

| SYMBOL     | R1*   | R2*   | LTP*   | S1*   | S2*   |
|------------|-------|-------|--------|-------|-------|
| ITC        | 262   | 263   | 260    | 257   | 254   |
| JIOFIN     | 209   | 210   | 207.24 | 205   | 203   |
| JSWSTEEL   | 1270  | 1288  | 1252.7 | 1231  | 1210  |
| KOTAKBANK  | 445   | 447   | 442.5  | 440   | 438   |
| LT         | 3703  | 3741  | 3665.1 | 3638  | 3610  |
| M&M        | 2871  | 2884  | 2858.4 | 2843  | 2827  |
| MARUTI     | 11543 | 11637 | 11450  | 11273 | 11097 |
| MAXHEALTH  | 858   | 870   | 845    | 836   | 828   |
| NESTLEIND  | 1187  | 1194  | 1180.5 | 1167  | 1153  |
| NTPC       | 306   | 310   | 301.8  | 299   | 296   |
| ONGC       | 231   | 233   | 229.85 | 227   | 224   |
| POWERGRID  | 255   | 258   | 251.75 | 247   | 242   |
| RELIANCE   | 1205  | 1213  | 1196.2 | 1186  | 1176  |
| SBILIFE    | 1651  | 1669  | 1633   | 1615  | 1597  |
| SBIN       | 959   | 973   | 945.1  | 938   | 931   |
| SHRIRAMFIN | 837   | 851   | 823.6  | 815   | 805   |
| SUNPHARMA  | 1766  | 1781  | 1751.2 | 1738  | 1725  |
| TATACONSUM | 1014  | 1028  | 1000   | 972   | 943   |
| TATASTEEL  | 173   | 175   | 171.42 | 169   | 166   |
| TCS        | 2533  | 2569  | 2496.9 | 2463  | 2430  |
| TECHM      | 1828  | 1845  | 1811.4 | 1778  | 1744  |
| TITAN      | 4395  | 4425  | 4365.9 | 4318  | 4271  |
| TMPV       | 264   | 266   | 261.2  | 260   | 258   |
| TRENT      | 2851  | 2880  | 2820.6 | 2768  | 2716  |
| ULTRACEMCO | 11217 | 11284 | 11150  | 11052 | 10954 |

\*R1 - Resistance 1 | \*R2 - Resistance 2 | \*LTP – Last Traded Price | \*S1 - Support 1 | \*S2 - Support 2

## Our Research Team

| Name              | Email ID                                                                           |
|-------------------|------------------------------------------------------------------------------------|
| Ajit Mishra       | <a href="mailto:ajit.mishra@religare.com">ajit.mishra@religare.com</a>             |
| Abhijeet Banerjee | <a href="mailto:abhijeet.banerjee@religare.com">abhijeet.banerjee@religare.com</a> |
| Gaurav Sharma     | <a href="mailto:gauravsharma2@religare.com">gauravsharma2@religare.com</a>         |
| Ashwani Harit     | <a href="mailto:ashwani.harit@religare.com">ashwani.harit@religare.com</a>         |
| Divya Parmar      | <a href="mailto:divya.parmar@religare.com">divya.parmar@religare.com</a>           |
| Rajan Gupta       | <a href="mailto:rajan.gupta1@religare.com">rajan.gupta1@religare.com</a>           |
| Vivek Chandra     | <a href="mailto:vivek.chandra@religare.com">vivek.chandra@religare.com</a>         |
| Himanshu Gupta    | <a href="mailto:himanshu.gupta1@religare.com">himanshu.gupta1@religare.com</a>     |

28 October 2026

*Daily*  
**Derivatives**

Before you use this research report, please ensure to go through the disclosure interalia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: [www.religareonline.com/disclaimer](http://www.religareonline.com/disclaimer)

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/are as under:

| S.No. | Statement                                                                                                                                                                                                                                     | Answer           |    |
|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|----|
|       |                                                                                                                                                                                                                                               | Tick Appropriate |    |
|       |                                                                                                                                                                                                                                               | Yes              | No |
| 1.    | I/we or any of my/our relative has any financial interest in the subject company? (If answer is yes, nature of interest is given below this table)                                                                                            |                  | No |
| 2.    | I/we or any of my/our relatives, have actual/beneficial ownership of one per cent. or more securities of the subject company, at the end of the month immediately preceding the date of the research report or date of the public appearance? |                  | No |
| 3.    | I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of the public appearance?                                                                        |                  | No |
| 4.    | I/we have received any compensation from the subject company in the past twelve months?                                                                                                                                                       |                  | No |
| 5.    | I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?                                                                                                                              |                  | No |
| 6.    | I/we have received any compensation for brokerage services from the subject company in the past twelve months?                                                                                                                                |                  | No |
| 7.    | I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?                                                                                                         |                  | No |
| 8.    | I/we have served as an officer, director or employee of the subject company?                                                                                                                                                                  |                  | No |
| 9.    | I/we have been engaged in market making activity for the subject company?                                                                                                                                                                     |                  | No |

2014 is/are as under:

Statements of ownership and material conflicts of interest, compensation – Research Analyst (RA)

Nature of Interest [If answer to f (a) above conflicts is Yes

.....]

Name(s) with Signature(s) of RA(s).

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to

**Copyright:** This document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.